Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NYSE:DNA NASDAQ:GOSS NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$3.25-3.6%$2.85$1.20▼$6.23$191.87M2.93753,983 shs1.11 million shsDNAGinkgo Bioworks$10.02-4.0%$12.00$5.00▼$16.85$618.04M1.51.57 million shs1.46 million shsGOSSGossamer Bio$3.46$2.08$0.66▼$3.60$786.74M1.954.08 million shs4.24 million shsPROKProKidney$2.48-16.8%$2.79$0.46▼$7.13$876.96M1.742.01 million shs8.25 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-3.56%+10.54%+17.33%+40.69%-46.94%DNAGinkgo Bioworks-4.21%-9.85%-25.06%+12.09%+60.83%GOSSGossamer Bio0.00%+17.69%+75.63%+179.03%+288.72%PROKProKidney-16.78%+10.22%+4.64%+195.84%+3.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$3.25-3.6%$2.85$1.20▼$6.23$191.87M2.93753,983 shs1.11 million shsDNAGinkgo Bioworks$10.02-4.0%$12.00$5.00▼$16.85$618.04M1.51.57 million shs1.46 million shsGOSSGossamer Bio$3.46$2.08$0.66▼$3.60$786.74M1.954.08 million shs4.24 million shsPROKProKidney$2.48-16.8%$2.79$0.46▼$7.13$876.96M1.742.01 million shs8.25 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-3.56%+10.54%+17.33%+40.69%-46.94%DNAGinkgo Bioworks-4.21%-9.85%-25.06%+12.09%+60.83%GOSSGossamer Bio0.00%+17.69%+75.63%+179.03%+288.72%PROKProKidney-16.78%+10.22%+4.64%+195.84%+3.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 3.14Buy$11.67258.97% UpsideDNAGinkgo Bioworks 2.33Hold$9.50-5.19% DownsideGOSSGossamer Bio 3.00Buy$8.50145.66% UpsidePROKProKidney 2.33Hold$6.25152.02% UpsideCurrent Analyst Ratings BreakdownLatest BDTX, GOSS, PROK, and DNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025GOSSGossamer BioCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/3/2025BDTXBlack Diamond TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.009/3/2025BDTXBlack Diamond TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.008/25/2025DNAGinkgo BioworksBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$6.00 ➝ $9.008/18/2025PROKProKidneyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/11/2025BDTXBlack Diamond TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025BDTXBlack Diamond TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.008/8/2025DNAGinkgo BioworksCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/6/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $5.007/15/2025PROKProKidneyUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.00 ➝ $8.007/14/2025GOSSGossamer BioScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSector Outperform$11.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond TherapeuticsN/AN/AN/AN/A$1.47 per shareN/ADNAGinkgo Bioworks$227.04M2.61N/AN/A$13.17 per share0.76GOSSGossamer Bio$114.70M6.86N/AN/A$0.13 per share26.62PROKProKidney$80K9,122.68N/AN/A($3.41) per share-0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$69.68M$0.2314.13N/AN/AN/A12.70%9.58%11/4/2025 (Estimated)DNAGinkgo Bioworks-$547.03M-$5.86N/AN/AN/A-136.56%-43.25%-22.29%11/11/2025 (Estimated)GOSSGossamer Bio-$56.53M-$0.62N/AN/AN/A-344.81%-1,774.72%-46.73%11/6/2025 (Estimated)PROKProKidney-$61.19M-$0.57N/AN/AN/AN/AN/A-17.11%11/11/2025 (Estimated)Latest BDTX, GOSS, PROK, and DNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025PROKProKidney-$0.14-$0.13+$0.01-$0.13N/A$0.22 million8/7/2025Q2 2025BDTXBlack Diamond Therapeutics-$0.25-$0.19+$0.06-$0.19N/AN/A8/7/2025Q2 2025DNAGinkgo Bioworks-$1.44-$1.10+$0.34-$1.10$41.60 million$49.60 million8/5/2025Q2 2025GOSSGossamer Bio-$0.18-$0.17+$0.01-$0.17$4.12 million$11.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.738.73DNAGinkgo BioworksN/A5.415.41GOSSGossamer Bio6.704.404.40PROKProKidneyN/A11.4811.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%DNAGinkgo Bioworks78.63%GOSSGossamer Bio81.23%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics5.97%DNAGinkgo Bioworks9.72%GOSSGossamer Bio6.70%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.94 million53.54 millionOptionableDNAGinkgo Bioworks64059.20 million53.45 millionOptionableGOSSGossamer Bio180227.38 million212.15 millionOptionablePROKProKidney3294.28 million172.18 millionOptionableBDTX, GOSS, PROK, and DNA HeadlinesRecent News About These CompaniesProKidney Leads Our Trio Of Promising Penny StocksSeptember 12 at 9:46 AM | finance.yahoo.comProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comNuveen LLC Makes New Investment in ProKidney Corp. $PROKSeptember 8, 2025 | marketbeat.comProKidney Corp. (NASDAQ:PROK) Receives $6.25 Consensus Target Price from BrokeragesSeptember 6, 2025 | americanbankingnews.comProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 4, 2025 | marketbeat.comChronic Kidney Disease Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsightSeptember 3, 2025 | theglobeandmail.comProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comProKidney (NASDAQ:PROK) Trading Down 5.6% - What's Next?September 3, 2025 | marketbeat.comProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare ConferenceAugust 27, 2025 | globenewswire.comProKidney (NASDAQ:PROK) Cut to Hold at Zacks ResearchAugust 22, 2025 | marketbeat.comProKidney Corp. (NASDAQ:PROK) Sees Large Decline in Short InterestAugust 21, 2025 | marketbeat.comProKidney (NASDAQ:PROK) Shares Down 6.9% - What's Next?August 21, 2025 | marketbeat.comProKidney (NASDAQ:PROK) Stock Price Up 8.1% - Here's What HappenedAugust 20, 2025 | marketbeat.comProKidney (NASDAQ:PROK) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPSAugust 15, 2025 | marketbeat.comProKidney Reports 78 Percent Gain in Q2August 14, 2025 | theglobeandmail.comCiti Reaffirms Their Buy Rating on ProKidney (PROK)August 14, 2025 | theglobeandmail.comProKidney reports larger second-quarter loss as key studies continueAugust 14, 2025 | journalnow.comJProKidney Corp. Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comProKidney reports Q2 EPS (13c), consensus (14c)August 12, 2025 | msn.comProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical UpdatesAugust 12, 2025 | globenewswire.comProKidney Corp. (PROK) - Yahoo FinanceAugust 9, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDTX, GOSS, PROK, and DNA Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$3.25 -0.12 (-3.56%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.27 +0.02 (+0.62%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Ginkgo Bioworks NYSE:DNA$10.02 -0.42 (-4.02%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$10.05 +0.03 (+0.26%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Gossamer Bio NASDAQ:GOSS$3.46 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.48 +0.02 (+0.46%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.ProKidney NASDAQ:PROK$2.48 -0.50 (-16.78%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.50 +0.02 (+0.97%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
